

**Table S1. The primers used for qRT-PCR experiments****Table 1.**

Names	Sequences
<i>BNP (rat)</i>	Forward: 5'- GCTGCTGGAGCTGATAAGAGA-3' Reverse: 5'- CGCCGATCCGGTCTATCTTC-3'
<i>NPRA (rat)</i>	Forward: 5'- CCTTCAGGCTGCCAAAAT -3' Reverse: 5'- ATCCTCCACGGTGAAGTTGA-3'
<i>GAPDH (rat)</i>	Forward: 5'-GAACGGGAAGCTCACTGG-3' Reverse: 5'-GCCTGCTTCACCACCTTCT-3'
<i>VDR (human)</i>	Forward: 5'- GTGGACATCGGCATGATGAAG-3' Reverse: 5'- GGTCGTAGGTCTTATGGTGGG-3'
<i>Actin (human)</i>	Forward: 5'- CTCCATCCTGGCCTCGCTGT -3' Reverse: 5'- GCTGTCACCTTCACCGTTCC-3'
<i>BNP (human)</i>	Forward: 5'- CAGCTCTGCATCGTGGATT-3' Reverse: 5'-CATCTCCTCCCAAAGCAGCC-3'

**Table S2. The primers used for CHIP assays****Table 2.**

	Sequences
<i>H-NPPB-Site 1</i>	Forward: 5'- ATCCTGTGTTGGCTTGGTGG-3' Reverse: 5'- TGAGAGATAGGGTCCAGTGATGA-3'
<i>H-NPPB-Site 2</i>	Forward: 5'- ATGGCGGATTGTGAGAGCAT-3' Reverse: 5'- CCGAGGAACTTGGAGCAAA-3'

**Luciferase assay promoter**> NPPB -Promoter-WT1

agatgaaggaggcactggagagggaaatccccatatctctgttatccagcaaataccatcattcc  
 agccatcctttgtttcttcttccttcttcttcttcttcttcttcttcttcttgcctctgtcaaccaggctgga  
 gtgcagtggcgtgatctcagtcactgcaacctccacccctgggtcaagtgattctcctcagcctcccgag  
 tagctggactacaggcgccctgccaccatgcccagctaattttgtaatttttagtagagacgggattcaccgtg  
 gtctcgatctcctgacctcgtgatccgaccgcctcgccctctcaaagtgcgtggattacaggcgtgaaccacat

```
ggccagcctatcctttccatccgtgtggctggggggagaggaggtgtacacgtggaggacac  
acatataaggcattcttgggtgactcgtcatcactggaccctatctctaaaattccagcgaatctgc
```

> NPPB -Promoter-WT2

cccggtgctgttaaggactataagatggcggattgtgagagcatagggaaaggctcggaggctctgtccttg  
ctccacgcaggctttctggcctgaaaatccgttgaagagagcagctctgagagttgctccaagttccctcg  
ggtgatcagcaccacggacagcggccagggcgccccgaggacccgcaggcaggcagggtgcacagcgg  
cgagcaggtgctgcgctacgtgcggccagggactcgcgccccgagggagaggcgccgcgggtggcg  
gggtcttggccgggctgtttcgctgtgagtcacccgtgctcccgcgctcacgtcggtcctcgaaagccgg  
ggtcctccctgcctttccagcaacggtgtgggtggggaggcaggaagaagcgccaaccttaggacac

> NPPB -Promoter-MT1

> NPPB -Promoter-MT2

Cccgttgtactggactataagatggcgattgtgagagcataggaaaggctcgaggctctgtccttg  
ctccacgcaggctttctggcctgaaaatccgtgaagagagcagctctgagagttgcgtccaagtccctegg


ggtgatcagcaccacggacagcggccagggcgccccgaggaccgcaggcaggcggagatcacagcggc  
gagcaggtgctgcgctacgtcgccggcaggaaactcgcgccgggaggggagaggcgcgggtggcgg  
ggtcttggccgggctgtttcgctgtgagtcccccgtgtcccgctcacgtcggtcctcgaaagccgg  
gtcctccctgcctttccagcaacggtgggtgggaggcaggaagaaagcgccaacctaggacac

>R-Nppb-promoter


gctctaaagcacctcagtcaccccccagcactggcggtttttactgtgttagttgagatgagaagacccact  
gtgagtgtccccactttatggatgggtcctggaccacataagtggagagagagagaaagagagagaca  
gacagacaggcagacagagacagagagacagagacagggacagagacagacagacagagagact  
agacagagacagagacagagacagagacagagacagggcagacagagacagagacagagagagaga  
gagagagagagagagagatgaattcactgctctgtccctgatggatgttacataaccaatggct  
tcaagctcgtccacaggcaatgctgatagaagtgttagacagtggaaacctatctcagaggagatggatc  
tatcaggaacttggctggagccacttgtatgacatgtggcaagaatctgacttcattgcctgtcctgag  
aatttactgaaactgatgtgggatggtaggctaattgtccctcagagggaaattgtgtgagaaggtaggg  
gtttgagtgcctcgactggacttcaagtctaaaaatgcaaattcacataacaagaaagctgcagctaaatg  
aagctgggggtggctctgcccctgaaaacaatagcttaggagagatgtgtctccctgggtcagaacaca  
gaacctcacataaacaggggtccaagaagccccgaggctgcagaagaacctgacagttctccaaatgtga  
ctggttgggctcatgaccccttaactatcccttcttatcttacccactgccactcctggactgccc  
ttgaccaacctgaccctgtgaacatagattctgcagaaggatagtgcacattggccacacacctgggttata  
cccacagcctcattcctcagagtctcatttcacccatgtctgggtgtcgagggagaagtcactca  
tggctgatcagctgagagctggaaagaggccctccacatgtctgggtgtctaggcacccttctttactcg  
ggtgtggagggacattggcacctggagatgccccagaaggcattgtgtgacccctgtcttggccagg

atgaaaattctatctaattcagctctttttaaggggctggagttccagaagttccattaccagcttt  
gtcatttgaatattggagagtgagcatttgagctgaaatcttcacagggtttgaggggtggggagtactgga  
aggtggggcagggtatcagagtggcgtagccacctagctcctctggcctggagatcagtggagaaga  
gaactgaaagttgtgtgaaggtcacgtgtggtgcataaccatggacagctaccagagtgcggaaagt  
gtgcagcccgccctacagctagatgcctggtagccggcagggcctggattacaggttcgaggacactctc  
cagagaggctggatggtggtgctaactggaagtgttttgcatacccccataagccccacacccgccc  
caggctggaaaactgggttctccctgtcattccaatacggtgcccacggtattaaaggccctcaggttt  
gcatgatagaaggcagggacaacaaggacctgttagtgtccccacacactccaccctagccagccatg  
cctatacaaggcctgcggttatagcctccacccacaacgaacactccacagaggcacagagggtgaattctc  
aggcctgagctcagcaggcaggaatgtgtctgataaatcagagataacccacccctactccatgagaagg  
ctggccggacacccagccccaggataaaaggcagaggcaccgttgctgagaggctagtgcacgcgagctgct  
tgccggag

(The highlighted part represents the mutation site)



**Figure S1.** The diagram of the sequential experimentations. (a) The cochlea was removed from the P0 rat, and the middle turn of the spiral ganglions (SGs) was carefully separated from the spiral plate, cut into equal 300 to 500  $\mu\text{m}$  sections, and transferred to 15 mm culture dishes. (b) The cochlea was removed from the P0 rat. Then, SGs were separated from the cochlea and enzymatically dissociated into single cells, culturing in 15 mm culture dishes. (c) Transparent larvae were isolated and randomly divided into different groups. The observation was made after incubation for 24-48 hours.



**Figure S2.** The inhibition of the GMP-PKG pathway stopped the pro-neurogenic effects of vitamin D. (a) SG explants were cultured in 10 nM vitamin D plus 1  $\mu$ M NPR-A antagonist A71915, or 10 nM vitamin D plus 1  $\mu$ M PKG inhibitor KT5823 followed by fluorescence immunostaining analysis. The results showed no significant difference in the number and length of neurites compared with the control group (b) Zebrafish larva was cultured in 10 nM vitamin D plus 1  $\mu$ M A71915 and 10 nM vitamin D plus 1  $\mu$ M KT5823. The results showed no significant difference in the number and length of neurites compared with the control group. Arrows indicate complete and countable neurons.